% | $
Quotes you view appear here for quick access.

Heron Therapeutics, Inc. Message Board

  • mazurek2050 mazurek2050 Apr 1, 2013 3:13 PM Flag

    Jefferies statement:

    Jefferies reiterated its Buy rating but lowered its price target on AP Pharma (OTC: APPA) from $1.50 to $1.25 after the FDA Complete Response Letter (CRL) for APF530 for chemotherapy induced nausea and vomiting (CINV).

    "We believe the concerns expressed in the CRL are straightforward and we believe that the company's timeline to launch in 1H14 is reasonable given the characterization of the issues and our understanding of the rate limiting steps to refiling," analyst Thomas Wei comments